Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/153876 |
Resumo: | Warfarin is the most used anticoagulant in primary health care. Due to the narrow therapeutic index, its users are more susceptible to adverse events. The objective of this study was to describe the itinerary of the public health sector patients for resolution of adverse events related to warfarin. It is a prospective open cohort, held for a period of 18 months with warfarin users of the Brazilian public health system. Data were collected by monthly interviews and from patient records. Results: Sixty nine patients were interviewed, 64 of them completed monitoring and five died. Bleeding and venous thromboembolism were more frequent in patients starting treatment. It was observed that when adverse events have occurred, in most cases the patient held self-care at home (57%). During the follow-up, five patients were hospitalized for bleeding. Approximately half of the patients did not present their INR exams to the doctor. Conclusions: This study demonstrates weaknesses in caring for these patients and the need to accompany them, aiming to standardize and guide the itinerary of the anticoagulated patient to solve their problems and improve safety in drug treatment, with less cost to the public health system. |
id |
USP-31_871a4a1c4ad601f5ba61b75244a4c302 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/153876 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern BrazilWarfarin/adverse drugCohort studiesHealth services accessibilityReactionBrazilWarfarin is the most used anticoagulant in primary health care. Due to the narrow therapeutic index, its users are more susceptible to adverse events. The objective of this study was to describe the itinerary of the public health sector patients for resolution of adverse events related to warfarin. It is a prospective open cohort, held for a period of 18 months with warfarin users of the Brazilian public health system. Data were collected by monthly interviews and from patient records. Results: Sixty nine patients were interviewed, 64 of them completed monitoring and five died. Bleeding and venous thromboembolism were more frequent in patients starting treatment. It was observed that when adverse events have occurred, in most cases the patient held self-care at home (57%). During the follow-up, five patients were hospitalized for bleeding. Approximately half of the patients did not present their INR exams to the doctor. Conclusions: This study demonstrates weaknesses in caring for these patients and the need to accompany them, aiming to standardize and guide the itinerary of the anticoagulated patient to solve their problems and improve safety in drug treatment, with less cost to the public health system.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-11-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/15387610.1590/s2175-97902018000317738Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 3 (2018); e17738Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 3 (2018); e17738Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 3 (2018); e177382175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/153876/150223Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessColet, ChristianeAmador, Tânia AlvesHeineck, Isabela2019-03-17T13:19:36Zoai:revistas.usp.br:article/153876Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-03-17T13:19:36Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil |
title |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil |
spellingShingle |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil Colet, Christiane Warfarin/adverse drug Cohort studies Health services accessibility Reaction Brazil |
title_short |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil |
title_full |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil |
title_fullStr |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil |
title_full_unstemmed |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil |
title_sort |
Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil |
author |
Colet, Christiane |
author_facet |
Colet, Christiane Amador, Tânia Alves Heineck, Isabela |
author_role |
author |
author2 |
Amador, Tânia Alves Heineck, Isabela |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Colet, Christiane Amador, Tânia Alves Heineck, Isabela |
dc.subject.por.fl_str_mv |
Warfarin/adverse drug Cohort studies Health services accessibility Reaction Brazil |
topic |
Warfarin/adverse drug Cohort studies Health services accessibility Reaction Brazil |
description |
Warfarin is the most used anticoagulant in primary health care. Due to the narrow therapeutic index, its users are more susceptible to adverse events. The objective of this study was to describe the itinerary of the public health sector patients for resolution of adverse events related to warfarin. It is a prospective open cohort, held for a period of 18 months with warfarin users of the Brazilian public health system. Data were collected by monthly interviews and from patient records. Results: Sixty nine patients were interviewed, 64 of them completed monitoring and five died. Bleeding and venous thromboembolism were more frequent in patients starting treatment. It was observed that when adverse events have occurred, in most cases the patient held self-care at home (57%). During the follow-up, five patients were hospitalized for bleeding. Approximately half of the patients did not present their INR exams to the doctor. Conclusions: This study demonstrates weaknesses in caring for these patients and the need to accompany them, aiming to standardize and guide the itinerary of the anticoagulated patient to solve their problems and improve safety in drug treatment, with less cost to the public health system. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-11-29 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/153876 10.1590/s2175-97902018000317738 |
url |
https://www.revistas.usp.br/bjps/article/view/153876 |
identifier_str_mv |
10.1590/s2175-97902018000317738 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/153876/150223 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 3 (2018); e17738 Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 3 (2018); e17738 Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 3 (2018); e17738 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222913817739264 |